Furthermore, a substantial body of preclinical studies suggest that tumours with persistent Akt activation have heightened responses to inhibition of the mammalian target of rapamycin (mTOR) (Neshat et al, 2001; DeGraffenried et al, 2004; Gera et al, 2004). Here, AKT1 is linked to neoplasm.